PCORI is accepting applications for up to $30 million in funding to support innovative, high-impact, COVID-19-related studies that strengthen the understanding of different approaches to mitigate the impact of COVID-19 on individuals, communities, healthcare providers, and healthcare systems; and provide evidence to inform clinical and public health responses, decision making, and planning. Priority areas include:
- Adaptations to health care delivery
- Impact of COVID-19 on vulnerable populations
- Impact of COVID-19 on healthcare workforce well-being, management, and training
Proposals must fit clearly within the core mission of patient-engaged and patient-centered comparative clinical effectiveness research. PCORI is waiving its usual Letter of Intent process for proposals. The deadline for submission is May 26, 2020, and grant recipients will be announced in July.
PCORI is also accepting applications today for two funding opportunities under a more traditional timeline. Up to $20 million in funding is available for Observational Analyses of Second-Line Pharmacological Agents in Type 2 Diabetes and up to $25 million in funding is available for Conducting Rare Disease Research using PCORnet®. Both PFAs have a Letter of Intent deadline of June 2, 2020; applicants who are invited to submit a full proposal will then have until September 1, 2020.